Adaptive Biotechnologies Corpor (ADPT) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $12.96: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.
Adaptive Biotechnologies provides immune medicine products including clonoSEQ (FDA-authorized NGS assay for MRD detection in blood cancers) and immune medicine research/licensing services. Revenue of $277M in 2025 was 77% driven by the MRD business ($212.3M); clonoSEQ is used in... Read more
Sell if holding. Engine safety override at $12.96: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.6/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Adaptive Biotechnologies Corpor
Latest news
- Adaptive Biotechnologies COO Julie Rubinstein sells $270k in stock - Investing.com — Investing.com negative
- Why Adaptive Biotechnologies Stock Is Sinking Now - TipRanks — TipRanks negative
- Adaptive Biotechnologies (ADPT) moves 5.8% higher: Will this strength last? - MSN — MSN positive
- Adaptive Biotechnologies (ADPT) moves 5.8% higher: Will this strength last? - msn.com — msn.com positive
- Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means - AOL.com — AOL.com negative
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductclonoSEQ10-K Item 1: 'Total MRD revenue in 2025 was $212.3 million, representing 46% growth from 2024. We grew clonoSEQ test volume to 105,587 tests delivered'
- HIGHSupplierIllumina10-K Item 1A: 'Illumina supplies us with reagents that have been designed for use solely with these sequencers and Illumina is the sole provider of maintenance and repair services'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -16.8%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $12.96: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.0:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $12.12. Score 5.6/10, moderate confidence.
Take-profit target: $17.52 (+35.2% upside). Prior stop was $12.12. Stop-loss: $12.12.
Concentration risk — Product: clonoSEQ; Concentration risk — Supplier: Illumina; Quality below floor (3.1 < 4.0).
Adaptive Biotechnologies Corpor trades at a P/E of N/A (forward -49.7). TrendMatrix value score: 7.6/10. Verdict: Sell.
14 analysts cover ADPT with a consensus score of 4.2/5. Average price target: $20.
What does Adaptive Biotechnologies Corpor do?Adaptive Biotechnologies provides immune medicine products including clonoSEQ (FDA-authorized NGS assay for MRD...
Adaptive Biotechnologies provides immune medicine products including clonoSEQ (FDA-authorized NGS assay for MRD detection in blood cancers) and immune medicine research/licensing services. Revenue of $277M in 2025 was 77% driven by the MRD business ($212.3M); clonoSEQ is used in 180+ active biopharmaceutical trials and by over 300M covered lives.